{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-010408","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.354433+00:00","generated_at":"2026-05-15T11:09:18.233933+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abeona reports $71.2M net income in FY 2025; first ZEVASKYN patient treated","bullets":["First ZEVASKYN commercial patient treated in Dec 2025; net product revenue $2.4M; one patient treated in Q1 2026 with more biopsies collected.","Total revenue $5.8M including $3.4M license revenue from Taysha milestone; PRV sale net gain $152.4M.","Net income $71.2M ($1.34 basic EPS) vs loss of $63.7M in 2024; cash $191.4M as of Dec 31, 2025.","R&D spend decreased to $26.8M; SG&A increased to $65.0M due to commercial transition post-FDA approval.","Expanding patient access: fourth QTC activated at UTMB Galveston; building launch momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-010408","json":"https://secwatch.observer/filing/0001493152-26-010408.json","markdown":"https://secwatch.observer/filing/0001493152-26-010408.md","text":"https://secwatch.observer/filing/0001493152-26-010408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:09:18.233933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"246145707965bcf943f8e72ec41e7f1ad13a270a","claim":"ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.","evidence_excerpt":"Abeona reported total revenue of $5.8 million for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$5.8 million"},{"label":"Net income","value":"$71.2 million"},{"label":"EPS","value":"$1.34 per basic and $1.01 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"246145707965bcf943f8e72ec41e7f1ad13a270a","claim":"ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.","evidence_excerpt":"major academic medical center renowned for its expertise in comprehensive complex skin disease and wound care. Full Year 2025 Financial Results Abeona reported total revenue of $5.8 million for the year ended December 31, 2025. This was comprised of $3.4 million in license and other revenues and $2.4 million in net product revenue. License and other revenues were","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$5.8 million"},{"label":"Net income","value":"$71.2 million"},{"label":"EPS","value":"$1.34 per basic and $1.01 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}